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Summary
Opioid drugs, such as morphine, are among the most effec-
tive analgesics available. However, their utility for the treat-
ment of chronic pain is limited by side effects including
tolerance and dependence. Morphine acts primarily through
the mu-opioid receptor (MOP-R) [1], which is also a target of
endogenous opioids. However, unlike endogenous ligands,
morphine fails to promote substantial receptor endocytosis
both in vitro [2–5] and in vivo [6–11]. Receptor endocytosis
serves at least two important functions in signal transduc-
tion. First, desensitization and endocytosis act as an ‘‘OFF’’
switch by uncoupling receptors from G protein. Second,
endocytosis functions as an ‘‘ON’’ switch, resensitizing re-
ceptors by recycling them to the plasma membrane. Thus,
both the OFF and ON function of the MOP-R are altered in re-
sponse to morphine compared to endogenous ligands. To
examine whether the low degree of endocytosis induced by
morphine contributes to tolerance and dependence, we
generated a knockin mouse that expresses a mutant MOP-R
that undergoes morphine-induced endocytosis. Morphine
remains an excellent antinociceptive agent in these mice.
Importantly, these mice display substantially reduced anti-
nociceptive tolerance and physical dependence. These
data suggest that opioid drugs with a pharmacological pro-
file similar to morphine but the ability to promote endocyto-
sis could provide analgesia while having a reduced liability
for promoting tolerance and dependence.
Results
Generation of a Novel MOP-R Knockin Mouse
with Altered Trafficking Properties
To directly examine whether endocytosis of the MOP-R in re-
sponse to morphine alters the development of tolerance and
dependence in vivo, we generated a knockin mouse expressing
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Medical University Graz, Graz A-8010, Austria.the rMOP-R mutant receptor that internalizes in response to
morphine [12]. In this rMOP-R, a portion of the cytoplasmic
tail of the MOP-R, encoded entirely within exon 3, has been
replaced with sequence from the delta opioid peptide receptor
(see Figure 1A). Mice expressing the rMOP-R were identified by
Southern (DNA) blot analysis (Figures 1A and 1B). The specific
mutation introduced to the MOP-R gene [12] was contained en-
tirely within exon 3, which is common to all splice variants that
have been described. Endocytic trafficking of the wild-type
MOP-R and the rMOP-R mutant receptor examined in striatal
neurons cultured from wild-type and mutant mice demon-
strated that morphine promotes rMOP-R but not MOP-R endo-
cytosis in response to morphine (Figure 1C and Figure S1 avail-
able online).
The mutant mice were viable, had no gross phenotypic
abnormalities, and showed normal baseline pain responses
(hot-plate latency, 56C: wild-type, 4.88 6 0.33 s; mutant,
4.55 6 0.32 s). Consistent with their equivalent baseline pain
responses, there were no genotypic differences in MOP-R dis-
tribution in the spinal cord or multiple brain regions important
for the antinociceptive and reinforcing properties of opiates
(Figure S2 and data not shown). In addition, ligand affinity, re-
ceptor number, and receptor G protein coupling were unal-
tered in the rMOP-R mice (Figures 2A–2C).
Antinociception in rMOP-R Knockin Mice
versus Wild-Type MOP-R Mice
Morphine-induced antinociception was evaluated by measur-
ing response latencies in the hot-plate test. We tested a dose
of morphine (10 mg/kg) known to induce robust antinocicep-
tion in mice. The acute antinociceptive effect of this dose of
morphine was significantly enhanced and prolonged in knockin
mice relative to their wild-type littermates (Figure 3A). A dose
of 3 mg/kg in the mutant mouse was equi-antinociceptive to
10 mg/kg in the wild-type mouse (Figure 3B). Both genotypes
reached a ceiling effect at the highest dose tested, 50 mg/kg.
The opioid antagonist naloxone completely reversed the anti-
nociceptive effects of morphine in both wild-type and mutant
mice (Figure 3B).
We propose that the enhanced antinociception in the mutant
mice reflects the restoration of the ON function provided by
receptor endocytosis and recycling. Specifically, we propose
that morphine-occupied MOP receptors become partially
desensitized in wild-type mice and fail to resensitize due to
poor endocytosis; whereas in the rMOP-R knockin mice, re-
ceptors are also desensitized but are rapidly resensitized by
endocytosis and recycling. Consistent with this hypothesis,
MOP receptors in wild-type mice given a single 10 mg/kg
dose of morphine showed significant receptor-G protein
uncoupling (Figure 3C, left). Clearly not all MOP receptors
in these mice were desensitized because morphine is still an
excellent acute antinociceptive agent in wild-type mice. Nev-
ertheless, MOP-Rs in the brainstem of wild-type mice treated
with morphine showed a 200-fold shift in the EC50 of DAMGO
(Figure 3C, left) compared to wild-type mice treated with vehi-
cle. In contrast, receptors in rMOP-R mice given the same dose
of morphine, showed no desensitization (Figure 3C, right).
These data suggest that the reduced morphine antinociception
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(A) Schematic of targeting strategy. A Sal1-Sac1 genomic fragment containing the MOP-R sequence, including exons 2 and 3, was modified to contain the
rMOP-R sequence (inset). A cassette containing resistance to G418 (Fx-Neo) and flanked by Lox P sites was inserted in the intron downstream of exon 3 for
selection of ES clones.
(B) Detection of homologous recombinants. Genomic DNA was digested with BamHI and subjected to DNA hybridization with anw1.1kb BglII fragment (see
[A]). Targeted loci were confirmed by the presence of a band atw8 kb. The intact locus gave a band atw6 kb.
(C) Quantification of endocytosis. MetaMorph software was used to quantify the intensity of receptor signal at the plasma membrane versus the cytosol for
each treatment condition and each genotype (MOP-R in black, rMOP-R in white). Data is plotted as the ratio of signal located within 0.3 mm of the surface
(peripheral) versus the amount in the cytosol (central). See Figure S1 for representative neurons and schematic. Histogram shows the mean of this ratio 6
the SD for each treatment (10–25 measurements per condition; see the Supplemental Experimental Procedures.)in the wild-type compared to the rMOP-R mice reflects partial
desensitization of MOP-Rs that is not reversed by endocytosis
and recycling.
If this were the case, we would expect mice of both
genotypes to show equivalent antinociception to an agonist
that promotes endocytosis of the receptor in both genotypes.
Indeed, there were no significant genotypic differences in
antinociception induced by methadone (1–10 mg/kg; Fig-
ure 3D), a MOP-R agonist that promotes rapid internalization
of both the wild-type MOP-R and mutant rMOP-R. Thus, the
enhanced opioid antinociception observed in the rMOP-R
knockin mice is specific to morphine. Together with our im-
munohistochemical and pharmacological data (Figure S2
and Figure 2), these data suggest that the enhanced mor-
phine antinociception in the rMOP-R knockin mice cannot
be accounted for by differences in MOP-R distribution, ligand
affinity, receptor number, or receptor-G protein coupling.
Rather, these data suggest that facilitating MOP-R endocyto-
sis enhances morphine antinociception by reversing rapid
desensitization.
Acute Antinociceptive Tolerance in rMOP-R Knockin
Mice versus Wild-Type MOP-R Mice
It has been hypothesized that MOP-R desensitization contrib-
utes to acute morphine tolerance. If this were the case, rMOP-
R mice would be expected to develop reduced acute tolerance
compared to wild-type mice. To examine this, we evaluated
the acute antinociceptive effect of equi-antinociceptive doses
of morphine (3 mg/kg in rMOP-R and 10 mg/kg in MOP-R, see
Figure 3B) 24 hr after pretreatment with a high dose of mor-
phine (100 mg/kg) or saline. The day following pretreatment,
baseline response latencies between genotypes were similar
(rMOP-R, 5.76 6 0.47 s; MOP-R, 5.86, 6 0.51 s). Indicative of
the acute tolerance that is typically observed in this paradigm[13], wild-type MOP-R mice that had been pretreated with
100 mg/kg of morphine showed a 43% reduction in antinoci-
ception compared to mice that had received saline the day
before (Figure 4A). In contrast, the rMOP-R knockin mice
maintained similar levels of morphine antinociception regard-
less of whether they had received morphine or saline pretreat-
ment the day before (Figure 4A). Thus, the rMOP-R knockin
mice did not develop acute antinociceptive tolerance to
morphine.
Chronic Antinociceptive Tolerance in rMOP-R
Knockin Mice versus Wild-Type MOP-R Mice
Although acute tolerance to high doses of opioids is most
relevant to acute pain, during the treatment of chronic pain,
analgesic tolerance typically develops over the course of re-
peated administrations of moderate levels of drug. Thus, we
evaluated the development of tolerance after twice daily ad-
ministrations of morphine (10 mg/kg) over 5 days. Wild-type
mice in this paradigm developed antinociceptive tolerance
(Figure 4B, closed squares). In contrast, their rMOP-R litter-
mates, treated with the same dose of morphine (10 mg/kg) at
the same intervals, showed no evidence of tolerance, exhibit-
ing as much antinociception on the last day of drug treatment
as they did on the first day (Figure 4B, closed circles).
To rule out the possibility that the lack of tolerance in the
mutant mice was an artifact of enhanced morphine antinoci-
ception (Figures 3A and 3B), we treated a separate group of
knockin mice with an equi-antinociceptive dose of morphine
(3 mg/kg, see Figure 3B) given at the same intervals. These
rMOP-R knockin mice still showed reduced tolerance, main-
taining similar levels of antinociception over the course of
treatment (Figure 4B, triangles). Thus, reduced morphine toler-
ance in the knockin relative to wild-type mice cannot be attrib-
uted to enhanced morphine antinociception.
A Knockin Mouse with Altered Morphine Responses
131Figure 2. Pharmacological Characterization of
Wild-Type MOP-R and rMOP-R Knockin Mice
(A and B) Receptor-G protein coupling. Agonist-
mediated GTPgS binding was measured in brain
membranes of wild-type MOP-R (squares) and
rMOP-R knockin mice (circles) with increasing
concentrations of DAMGO or morphine. Data
were analyzed by nonlinear regression by using
GraphPad Prism software and are presented as
means 6 SEM of at least three experiments per-
formed in triplicate. There were no significant
genotypic differences in either EC50 or Emax.
(C) Ligand affinity and receptor number. [3H] Nal-
oxone binding in whole-brain membranes from
MOP-R and rMOP-R mice. Saturation binding as-
says were performed on membranes (50–100 mg
per well) with increasing concentrations of [3H]
naloxone (0–15 nM, 55.9Ci/mmol). Nonspecific
binding was measured in the presence of 10 mM
naloxone. Binding parameters were determined
by Scatchard analysis of specific binding. Data
are means 6 SEM of three experiments per-
formed in duplicate. There were no statistically
significant differences between the genotypes
(One way ANOVA with Tukey’s post-hoc test).
Bmax, maximum binding capacity; KD, dissocia-
tion constant.
antagonist should have no behavioral ef-
fect. However, morphine tolerant ani-
mals show substantial naloxone-precip-
itated withdrawal signs (for example, see
[14]), indicating that receptors continueThese results suggest that endocytosis of the receptor
reduces the development of antinociceptive tolerance. If this
were the case, one would expect that opiate agonists, such
as methadone, that promote endocytosis of the MOP-R would
have reduced liability for promoting tolerance in wild-type
mice. In addition, wild-type and rMOP-R mice should show
equivalent responsiveness to chronic methadone. To examine
this hypothesis, we evaluated the development of tolerance to
methadone in MOP-R and rMOP-R mice. In order to directly
compare tolerance to morphine versus methadone, we admin-
istered a dose of methadone (4 mg/kg, see Figure 3D) that was
equi-antinociceptive to the morphine dose we administered
in Figure 4B. At this dose, neither genotype showed evidence
of tolerance across treatment days (Figure 4C). In addition,
responsiveness to methadone during all treatment days was
equivalent in MOP-R (Figure 4C, squares) and rMOP-R
mice (Figure 4C circles). Thus, reduced chronic opioid toler-
ance in rMOP-R mice relative to MOP-R mice is specific to
morphine.
As was the case for reduced acute tolerance, reduced
chronic tolerance to morphine in the mutant mice may reflect,
at least in part, that MOP-Rs in the wild-type mice are desen-
sitized (Figure 3C) but are unable to resensitize due to poor en-
docytosis of the receptor. Facilitating receptor internalization
and recycling (i.e., restoring the ON function of endocytosis)
may protect against the development of both acute (Figure 4A)
and chronic tolerance (Figure 4B).
However, receptor desensitization alone cannot explain anti-
nociceptive tolerance to morphine. Specifically, if all MOP-Rs
were desensitized in morphine tolerant mice, then displace-
ment of morphine from these nonsignaling receptors withto signal actively in morphine tolerant
animals despite the lack of antinociception. Hence, mecha-
nisms other than receptor desensitization are likely contribut-
ing to tolerance.
Morphine Withdrawal in rMOP-R Knockin Mice versus
Wild-Type MOP-R Mice
We next examined whether facilitating endocytosis in the
rMOP-R mice affected the development of morphine depen-
dence. After chronic treatment with morphine, mice were chal-
lenged with the opioid antagonist, naloxone (2 mg/kg), 30 min
after the final morphine injection. Global withdrawal responses
were scored by an observer who was blind to genotype (Fig-
ure 4D). Wild-type mice expressed robust withdrawal re-
sponses compared to mutant mice, which were chronically
treated with the same amount of morphine (10 mg/kg) but at
a functionally higher dose (see Figures 3A and 3B). Consistent
with the hypothesis that enhanced receptor endocytosis de-
creases withdrawal, chronic methadone treatment (4 mg/kg
given at the same intervals as morphine) promoted substan-
tially less withdrawal than did morphine in wild-type mice (Fig-
ure 4D). In fact, the moderate level of methadone withdrawal
in wild-type mice was equivalent to that produced by either
morphine or methadone in the rMOP-R mice (Figure 4D).
Hence, we have generated a mouse line that retains morphine
antinociceptive potency with markedly reduced morphine
tolerance and dependence.
Discussion
In summary, we report that mice expressing a mutant rMOP-R
with altered receptor trafficking properties in response to
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132Figure 3. Antinociception in Wild-Type MOP-R and rMOP-R Knockin Mice
(A) Enhanced and prolonged morphine-induced antinociception in rMOP-R knockin mice. Antinociceptive responses were measured with the hot-plate
response latency test (56C) after morphine treatment (10 mg/kg, s.c.). A response endpoint was defined as latency to either lick the fore- or hindpaws
or flick the hindpaws. To avoid tissue damage, we exposed mice to the hot-plate for a maximum of 20 s. Data are reported as the mean 6 SEM of percent
maximum possible effect (MPE) by using the following formula: 100%3 [(drug response time – basal response time) / (20 s – basal response time)]. A two-
way analysis of variance revealed that the MPE curve for rMOP-R mice (n = 17) mice was significantly greater and prolonged relative to the MOP-R mice (n =
17), as indicated by a significant genotype [p < 0.001, F(1,7) = 28.05] and genotype 3 time interaction effect [p <0 .001, F(1,7) = 4.97].
(B) Dose-dependent morphine-antinociception. Antinociceptive responses were determined with the hot-plate test, and data are reported as mean6 SEM
of MPE (see [A]). Separate groups of mice for both genotypes (n = 7–9) were injected with the doses of morphine indicated and assessed for antinociception
30 min later. To test whether the antinociceptive responses were mediated by opioid receptors, we injected a final grouping with morphine (10 mg/kg) fol-
lowed by naloxone (2 mg/kg). rMOP-R knockin mice showed enhanced antinociception at 3 and 10 mg/kg doses (rMOP-R versus MOP-R scores for MPE at
respective morphine doses, Student’s t test, *p < 0.03) with the latter dose inducing the maximum possible response (100%) in the mutant mice. At the high-
est dose tested (50 mg/kg), both genotypes exhibited the maximum possible response (100%). For both genotypes, antinociception induced by 10 mg/kg of
morphine was reversed by treatment with 2 mg/kg of the opioid antagonist naloxone (morphine 10 mg/kg with and without naloxone 2 mg/kg treatment for
each genotype respectively, student’s t test +++p < 0.001).
(C) MOP-R desensitization in the brainstem following acute morphine treatment. Agonist-mediated [35S]GTPgS binding was measured in brainstem mem-
branes of MOP-R and rMOP-R mice with increasing concentrations of DAMGO. Left: Binding in MOP-R mice was significantly reduced (p < 0.01) after acute
morphine-treatment (10 mg/kg s.c. 30 min; EC50 = 4286 141 mM; open squares) compared to vehicle-treated mice (EC50 = 2.356 0.9 mM; closed squares).
Right: Binding in rMOP-R mice was not significantly changed (p > 0.05) after acute morphine treatment (EC50 = 3.29 6 1.4 mM; open circles) compared to
vehicle-treated mice (EC50 = 1.166 0.6 mM; closed circles). Data were analyzed by nonlinear regression using GraphPad Prism software and are presented
as means 6 SEM of at least three experiments performed in triplicate.
(D) Enhanced antinociception in rMOP-R knockin mice is morphine specific. Separate groups of mice for both genotypes (n = 8–10) were injected with the
doses of methadone indicated (1–10 mg/kg,) and assessed for antinociception. Methadone induced a dose-dependent increase in antinociceptive response
with no genotypic differences. For both genotypes, antinociception induced by 4 mg/kg of methadone was reversed by treatment with 2 mg/kg of the opioid
antagonist naloxone (methadone 4 mg/kg with and without naloxone 2 mg/kg treatment for each genotype respectively, Student’s t test, +++p < 0.001).
Thus, enhanced opioid-induced antinociception observed in the rMOP-R knockin mice is agonist specific and naloxone reversible.morphine show enhanced morphine-induced antinociception,
reduced morphine tolerance, and reduced naloxone-precipi-
tated withdrawal compared to their wild-type littermates.
These knockin mice otherwise show normal ligand affinity, re-
ceptor number, receptor-G protein coupling, and receptor dis-
tribution, consistent with the fact that both their basal pain re-
sponses as well as methadone antinociception are equivalent
to that of their wild-type littermates.These data are consistent with the hypothesis that
enhanced endocytosis of the MOP-R, in response to mor-
phine, can reduce antinociceptive tolerance and dependence
while retaining the antinociceptive efficacy of morphine. It is
important to note that endocytosis is only one step in a cas-
cade of highly conserved events that occurs after G-protein-
coupled receptor activation. When receptors are activated
by endogenous ligand, they are rapidly desensitized by
A Knockin Mouse with Altered Morphine Responses
133Figure 4. Opioid Tolerance and Dependence in MOP-R Wild-Type and rMOP-R Knockin Mice
(A) Acute morphine tolerance. Mice (n = 9) were initially treated with either saline (gray bars) or a high dose of morphine (100 mg/kg s.c., black bars). 24 hr
later, mice were challenged with an acute equi-antinociceptive dose of morphine (3 mg/kg for rMOP-R and 10 mg/kg for MOP-R, see Figure 4B). Data are
presented as mean 6 SEM of MPE. Wild-type MOP-R mice exhibited significant acute tolerance, showing a 43% reduction in MPE when pretreated with
100 mg/kg of morphine compared to saline 24 hr before (MOP-R comparing saline versus morphine pretreatment, Student’s t test, ***p < 0.001). In contrast,
rMOP-R knockin mice showed no evidence of tolerance and maintained the same level of morphine-induced antinociception whether they were pretreated
with 100 mg/kg of morphine or saline 24 hr before.
(B) Chronic morphine tolerance. Mice were treated twice daily with morphine (10 mg/kg, sc) for 5 days and antinociception was assessed after the first
injection of morphine each day. Mean 6 SEM of MPE across days are presented. A two-way ANOVA revealed that mice treated chronically with morphine
(n = 17) behaved differently corresponding to genotype, as indicated by a significant group effect [F(2,42) = 27.95, p < 0.001] and group 3 treatment days
effect [F(4,84) = 12.09, p < 0.001]. Posthoc comparisons (Tukey’s) revealed the source of the interaction. rMOP-R knockin mice treated with 10 mg/kg of
morphine had significantly longer response latencies across days compared to wild-type mice treated with the same dose of morphine (10 mg/kg) and
rMOP-R knockin mice chronically treated with a lower (equi-antinociceptive) dose of morphine (3 mg/kg) (rMOP-R 10 significantly different from MOP-R
10 and rMOP-R 3, **p < 0.01). Additionally, rMOP-R knockin mice chronically treated with an equi-antinociceptive dose of morphine (3 mg/kg) showed sig-
nificantly greater antinociception than did wild-type mice chronically treated with a higher dose of morphine (10 mg/kg) across the tolerance development
days (rMOP-R 3 versus MOP-R 10, ++p < 0.01). Only wild-type mice chronically treated with morphine (10 mg/kg) showed a significant decrease in antino-
ciception from Day 1 to Day 5 (MOP-R 10 Day 1 versus Day 5, ###p < 0.001). Thus, the development of antinociceptive tolerance to morphine was evident in
wild-type mice but attenuated in the knock in mice, whether they were chronically treated with the same (10 mg/kg) or equi-antinociceptive (3 mg/kg) dose of
morphine.
(C) Methadone tolerance. Mice were injected twice daily with methadone (4 mg/kg, sc) for 5 days. For both genotypes, there was no evidence of tolerance
development with both groups expressing comparable levels of methadone-antinociception following the first and last injection. Methadone antinocicep-
tion was equivalent in both genotypes across all days.
(D) Naloxone precipitated withdrawal. Groups of mice were chronically treated with 10 mg/kg of morphine (black bars, n = 10–12), 4 mg/kg of methadone
(gray bars, n = 9), or saline (white bars, n = 6) at the same intervals described for Figures 4B and 4C. Mice were challenged with naloxone (2 mg/kg, sc) 30 min
after the final treatment injection. Notably, the chronic dose of morphine used (10 mg/kg) corresponded to a functionally higher dose in the rMOP-R knockin
mice relative to wild-type mice (see Figures 3A and 3B). Standard withdrawal behaviors including jumping, ‘‘wet-dog’’ shakes, paw licks, and paw tremors,
were scored by an observer blind to genotype. Total withdrawal scores (the sum of all individual withdrawal behaviors) 6 SEM are presented and group
differences were analyzed with the LSD test. Compared to saline-treated mice, MOP-R wild-type mice displayed a significantly higher incidence of
withdrawal when chronically treated with morphine or methadone (MOP-R MOR versus MOP-R SAL, ***p < 0.001, MOP-R METH versus MOP-R SAL,
*p < 0.05), with a higher degree of withdrawal associated with chronic morphine treatment (MOP-R MOR versus MOP-R METH, ++p < 0.01). In contrast,
rMOP-R knockin mice displayed similar levels of withdrawal regardless of pretreatment drug. For rMOP-R knockin mice, both morphine and methadone
pretreatment resulted in similar levels of moderate withdrawal, comparable to methadone pretreatment in MOP-R wild-type mice.
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134phosphorylation and interaction with arrestin and then endo-
cytosed. After endocytosis, MOP-Rs are functionally resensi-
tized by recycling to the plasma membrane. Many groups
have demonstrated in vitro that morphine-activated receptors
elude this natural cycle of receptor desensitization, endocyto-
sis, and resensitization that is induced by endogenous MOP-R
ligands [15–18]. Similarly, morphine has been found to be
a poor inducer of receptor endocytosis in vivo [6–10]. How-
ever, in vivo, subtleties also emerge because in some cases
desensitization has not been detected [19], whereas in other
cases desensitization of the morphine-activated receptor
by GRK/arrestin and/or PKC does appear to occur [20–27].
Thus, receptor desensitization may be either brain region spe-
cific, incomplete, or both.
In the context of regionally-specific or incomplete receptor
desensitization, the failure to endocytose the morphine-bound
receptor has the potential to affect signal transduction in
at least two ways. First, in cells or brain regions where mor-
phine does not cause substantial receptor desensitization,
prolonged receptor activation may trigger downstream adap-
tive responses that contribute to morphine tolerance and de-
pendence. In rMOP-R mice, this prolonged receptor activation
is replaced by pulsatile receptor activation due to restoration
of the OFF/ON switch of endocytosis. Second, in cells or brain
regions where receptors do become desensitized after mor-
phine activation, failure to endocytose would prevent func-
tional resensitization of the receptor. In rMOP-R mice, resensi-
tization would be restored. Notably, even in regions where
desensitization appears to occur (Figure 3C), a significant
number of receptors remain coupled. These remaining recep-
tors would exhibit prolonged activation in wild-type mice and
pulsatile activation in knockin mice.
Disruption of arrestin enhances morphine antinociception
[21] and delay tolerance [21], presumably by decreasing the
degree of morphine-induced desensitization. However, ar-
restin knockout mice show levels of withdrawal equivalent to
their wild-type littermates [28], indicating that there are still
a substantial number of functionally coupled MOP-Rs even
in animals with intact arrestin. Promoting morphine-induced
endocytosis would be expected to both facilitate receptor re-
sensitization and alleviate the compensatory adaptive
changes associated with dependence. Thus, while both pre-
venting receptor desensitization and facilitating receptor en-
docytosis/resensitization are effective strategies to enhance
morphine antinociception and prevent tolerance, the latter
has the added benefits of reducing morphine dependence
and specificity to the MOP-R.
All opioids, when given at high enough concentration for
a long enough period of time, including methadone, can
induce tolerance and dependence. However, when given at
equi-antinociceptive doses, opioids induce different degrees
of tolerance and dependence [29–31] (see Figure 4C), and
some ligands even appear to cause these effects by different
mechanisms [32, 33]. Hence, given the complex pharmacology
of the various opioid ligands, it has been difficult to isolate the
effect of endocytosis on tolerance and dependence.
The present results provide a genetic ‘‘proof of concept’’
that endocytosis is an important mechanism that can delay tol-
erance and dependence. Notably, the use of the rMOP-R
knockin mice allowed the same opioid drug to be compared
in mice that appear to differ only in their MOP-R trafficking
properties. Importantly, even if mechanisms other than endo-
cytosis are contributing to the behavioral differences in the
MOP-R and rMOP-R mice, these mice will provide a powerfultool for delineating which of the adaptive changes that have
been observed in wild-type animals after chronic morphine
treatment are relevant to behavioral tolerance and depen-
dence.
Supplemental Data
Supplemental results, experimental procedures, and two figures are avail-
able at http://www.current-biology.com/cgi/content/full/18/2/129/DC1/.
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